FDA orders recall
THE FOOD and Drug Administration (FDA) has ordered the recall of one batch of an antiobesity pill from the market due to failed assay results based on laboratory analyses.
In an advisory, the FDA identified the product as Orlistat (Reducin) 120 mg capsule, manufactured by Shanxi Shuguang Pharmaceutical Co. Ltd. in Jinzhong, Shanxi, China, and distributed by Golden Dale Pharma Corp.
The batch number of the antiobesity pill being pulled out is DR-XY40428 with expiry date of October 2016.
The pill is used together with dietary modification in the management of obesity.
The FDA said the affected batch presented safety risks and potential adverse health consequences.
It advised distributors, retailers, hospitals, pharmacies and clinics that had the batch to discontinue sale or use of the product.
“All consumers are likewise advised,” the FDA said. Tina G. Santos
